Expertise in
7
conditions

Margitta M. Retz

Ismaninger Str. 22, 
Munich, BY, DE 
Expertise in
7
conditions
Ismaninger Str. 22, 
Munich, BY, DE 

Overview

Margitta Retz practices practicing medicine in Munich, Germany.

Retz is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Prostate Cancer, Cystectomy, and Lymphadenectomy.

They are actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 2 clinical trials.

Locations

Ismaninger Str. 22, Munich, BY 81675, Germany
Other Locations
Kuno Fischer Str. 8, Berlin, BE 14057, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 1 Less Clinical Trial

104 Total Publications

Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
Journal: Aktuelle Urologie
Published: July 24, 2026

Frequently Asked Questions about Margitta M. Retz

Is Margitta M. Retz a top-rated expert for Urothelial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Margitta M. Retz is classified as an Elite expert for Urothelial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Margitta M. Retz participate in research or clinical trials?

Yes. Margitta M. Retz has published 104 articles and abstracts on conditions like Urothelial Cancer. You can view a list of Margitta M. Retz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Retz's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile